Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and controlof a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelope

Vaccine-elicited antibodies specific for the third hypervariable domain of the surface gp120 of human immunodeficiency virus type 1 (HIV-1) (V3 loop) were assessed for their contribution to protection against infection in the simian-human immunodeficiency virus (SHIV)/rhesus monkey model. Peptide va ccine-elicited anti-V3 loop antibody responses were examined for their abil ity to contain replication of SHIV-89.6, a nonpathogenic SHIV expressing a primary patient isolate HIV-1 envelope, as well as SHIV-89.6P, a pathogenic variant of that virus. Low-titer neutralizing antibodies to SHIV-89.6 that provided partial protection against viremia following SHIV-89.6 infection were generated. A similarly low-titer neutralizing antibody response to SHI V-89.6P that did not contain viremia after infection with SHIV-89.6P was ge nerated, but a trend toward protection against CD4(+) T-lymphocyte loss was seen in these infected monkeys. These observations suggest that the V3 loo p on some primary patient HIV-1 isolates may be a partially effective targe t for neutralizing antibodies induced by peptide immunogens.